Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tiejun Gong
Long-Term Outcomes and Mutation Profiling of Patients With Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib
British Journal of Haematology
Hematology
Related publications
Improved Outcome for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Who Stop Ibrutinib +/− Rituximab for Reasons Other Than Progression of Disease
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma
Community Oncology
Combination of Ibrutinib With Rituximab (Ir) Is Highly Effective in Previously Untreated Elderly (>65 Years) Patients (Pts) With Mantle Cell Lymphoma (Mcl) - Phase Ii Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma
Cancer Discovery
Oncology
Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma
Haematologica
Hematology
Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma
British Journal of Haematology
Hematology
Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
